Latest & greatest articles for baclofen

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on baclofen or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on baclofen and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for baclofen

1. Baclofen for alcohol use disorder. (PubMed)

Baclofen for alcohol use disorder. Alcohol use disorder (AUD) and alcohol-related impairments belong to the most widespread psychiatric disorders leading to specific psychophysical, affective and cognitive symptoms and consequences for psychosocial well-being and health. Alcohol consumption is increasingly becoming a problem in many developing regions and AUD prevalence is estimated at 4.1% worldwide, with highest prevalence in European countries (7.5%), and the North America (6.0 (...) %). Therapeutic approaches, including pharmacotherapy, play an important role in treating patients with AUD.To assess the efficacy and safety of baclofen for treating people with AUD, who are currently drinking, with the aim of achieving and maintaining abstinence or reducing alcohol consumption.We searched the Cochrane Drugs and Alcohol Specialised Register, CENTRAL, MEDLINE, Embase, two further databases and two clinical trials registries, conference proceedings, and the reference lists of retrieved

2018 Cochrane

2. Alcohol dependence: the risks of high-dose baclofen

Alcohol dependence: the risks of high-dose baclofen Prescrire IN ENGLISH - Spotlight ''Alcohol dependence: the risks of high-dose baclofen '', 1 November 2018 {1} {1} {1} | | > > > Alcohol dependence: the risks of high-dose baclofen Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Alcohol dependence: the risks of high-dose baclofen With high-dose (...) baclofen, there is an increased risk of epilepsy, infection, myocardial infarction or suicidal thoughts. Baclofen has been used as a muscle relaxant since the 1970s. In France, it has also been used orally since the 2000s, at higher doses, to reduce alcohol consumption or to help maintain abstinence among alcohol-dependent patients. At present, its use in alcohol dependence is governed by a temporary recommendation for use issued by the French Health Products Safety Agency (Agence française du

2018 Prescrire

3. Baclofen

Baclofen Top results for baclofen - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for baclofen The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

4. Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS)

Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS) Intrathecal baclofen (ITB) is a treatment option for patients with severe poststroke spasticity (PSS) who have not reached their therapy goal with other interventions.'Spasticity In Stroke-Randomised Study' (SISTERS) was a randomised, controlled, open-label, multicentre phase IV study to evaluate the efficacy

Full Text available with Trip Pro

2018 EvidenceUpdates

5. Baclofen as treatment for alcohol use disorders

Baclofen as treatment for alcohol use disorders Baclofen as treatment for alcohol use disorders – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2017\/11\/Screenshot-2017-11-06-12.46.36.png"]} Toggle search form Toggle navigation Evidence-based medicine for general practitioners Nov 06 2017 Baclofen as treatment for alcohol use disorders (...) By in , , Journal reference: Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2010 Nov;34(11):1849-57 Link: Published: November 2010 Evidence cookie says… Baclofen cannot be recommended as a routine treatment for alcohol use disorders the quality of the evidence is low overall some randomised trials demonstrate a beneficial effect, while others demonstrate

Full Text available with Trip Pro

2017 Morsels of Evidence

6. Baclofen as treatment for alcohol use disorders

Baclofen as treatment for alcohol use disorders Baclofen as treatment for alcohol use disorders – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2017\/11\/Screenshot-2017-11-06-12.46.36.png"]} Toggle search form Toggle navigation Evidence-based medicine for general practitioners Nov 06 2017 Baclofen as treatment for alcohol use disorders (...) By in , , Journal reference: Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2010 Nov;34(11):1849-57 Link: Published: November 2010 Evidence cookie says… Baclofen cannot be recommended as a routine treatment for alcohol use disorders the quality of the evidence is low overall some randomised trials demonstrate a beneficial effect, while others demonstrate

Full Text available with Trip Pro

2017 Morsels of Evidence

7. Baclofen for alcohol withdrawal. (PubMed)

Baclofen for alcohol withdrawal. Baclofen shows potential for rapidly reducing symptoms of severe alcohol withdrawal syndrome (AWS) in people with alcoholism. Treatment with baclofen is easy to manage and rarely produces euphoria or other pleasant effects, or craving for the drug. This is an updated version of the original Cochrane Review published in 2015, Issue 4.To assess the efficacy and safety of baclofen for people with AWS.We updated our searches of the following databases to March 2017 (...) : the Cochrane Drugs and Alcohol Group Specialised Register, CENTRAL, PubMed, Embase, and CINAHL. We also searched registers of ongoing trials. We handsearched the references quoted in the identified trials, and sought information from researchers, pharmaceutical companies, and relevant trial authors about unpublished or uncompleted trials. We placed no restrictions on language.We included all randomised controlled clinical trials (RCTs) evaluating baclofen versus placebo or any other treatment for people

Full Text available with Trip Pro

2017 Cochrane

8. Effect of baclofen on gastric acid pocket in subjects with gastroesophageal reflux disease symptoms. (PubMed)

Effect of baclofen on gastric acid pocket in subjects with gastroesophageal reflux disease symptoms. Postprandial gastroesophageal reflux (PGER) in the distal esophagus (DE) is associated with a gastric juice 'acid pocket' (AP). Baclofen reduces AP extension into the DE in healthy volunteers, in part through increased lower esophageal sphincter (LES) pressure. We aimed to verify whether baclofen also affects postprandial AP location and extent in gastroesophageal reflux disease (GERD) patients (...) . Thirteen treatment-naive heartburn-prevalent GERD patients underwent two AP studies, after pretreatment with baclofen 40 mg or placebo 30 minutes preprandially. We performed pH-probe stepwise pull-throughs (PT) (1 cm/min, LES -10 to +5 cm) before and every 30 minutes from 30 minutes before up to 150 minutes after a test meal. After the meal, both after placebo and baclofen, gastric pH significantly dropped at 30, 60, 90 minutes postprandially (P: nadir pHs of 3.9 ± 0.6, 2.3 ± 0.6, 2.1 ± 0.4; B: nadir

2017 Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus

9. Intrathecal baclofen for treating spasticity in children with cerebral palsy. (PubMed)

Intrathecal baclofen for treating spasticity in children with cerebral palsy. Cerebral palsy is a disorder of movement and posture arising from a non-progressive lesion in the developing brain. Spasticity, a disorder of increased muscle tone, is the most common motor difficulty and is associated with activity limitation to varying degrees in mobility and self care.Oral baclofen, a gamma-aminobutyric acid (GABA) agonist, has been used in oral form to treat spasticity for some time, but it has (...) a variable effect on spasticity and the dose is limited by the unwanted effect of excessive sedation. Intrathecal baclofen produces higher local concentrations in cerebrospinal fluid at a fraction of the equivalent oral dose and avoids this excessive sedation.To determine whether intrathecal baclofen is an effective treatment for spasticity in children with cerebral palsy.We searched the CENTRAL, MEDLINE, EMBASE and CINAHL databases, handsearched recent conference proceedings, and communicated

Full Text available with Trip Pro

2015 Cochrane

10. Baclofen for alcohol withdrawal. (PubMed)

Baclofen for alcohol withdrawal. The treatment baclofen shows potential for rapidly reducing symptoms of severe alcohol withdrawal syndrome (AWS) in people with alcoholism. Treatment with baclofen is easy to manage and rarely produces euphoria or other pleasant effects, or craving for the drug. This is an updated version of the original Cochrane review published in Issue 2, 2013.To assess the efficacy and safety of baclofen for people with AWS.We searched the Cochrane Drugs and Alcohol Group (...) companies, and relevant trial authors about unpublished or uncompleted trials. We placed no restrictions on language.We included all randomised controlled clinical trials (RCTs) evaluating baclofen versus placebo or any other treatment for people with AWS. We excluded uncontrolled, non-randomised, or quasi-randomised trials. We included both parallel group and cross-over studies.Two review authors independently assessed references retrieved for possible inclusion. Any disagreements were resolved

Full Text available with Trip Pro

2015 Cochrane

11. Baclofen and severe alcohol dependence: an uncertain harm-benefit balance as of early 2013

Baclofen and severe alcohol dependence: an uncertain harm-benefit balance as of early 2013 Prescrire IN ENGLISH - Spotlight ''Baclofen and severe alcohol dependence: an uncertain harm-benefit balance as of early 2013 '', 1 September 2013 {1} {1} {1} | | > > > Baclofen and severe alcohol dependence: an uncertain harm-benefit balance as of early 2013 Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |    (...) |   |   |   |  Spotlight Baclofen and severe alcohol dependence: an uncertain harm-benefit balance as of early 2013 FEATURED REVIEW More data are needed on the efficacy and adverse effects of baclofen in alcohol dependence, compared with other options. Patients who have received thorough, well-balanced information, and decide to try baclofen as a last resort should be included in comparative clinical studies. Full review (4 pages) available for download by subscribers

2014 Prescrire

12. Continuous intrathecal baclofen (ITB) infusion for severe spasticity and dystonia

Continuous intrathecal baclofen (ITB) infusion for severe spasticity and dystonia Continuous intrathecal baclofen (ITB) infusion for severe spasticity and dystonia Continuous intrathecal baclofen (ITB) infusion for severe spasticity and dystonia Malaysian Health Technology Assessment (MaHTAS) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Malaysian Health Technology Assessment (MaHTAS). Continuous intrathecal baclofen (ITB) infusion for severe spasticity and dystonia. Putrajaya: Malaysian Health Technology Assessment (MaHTAS). 2014 Authors' objectives To assess the safety, effectiveness, cost-effectiveness, organizational issues related to the use of continuous ITB infusion for treatment of patients with severe spasticity or severe dystonia or having both conditions compared with conventional treatment. Authors' conclusions

2014 Health Technology Assessment (HTA) Database.

13. Baclofen

Baclofen USE OF BACLOFEN IN PREGNANCY 0344 892 0909 USE OF BACLOFEN IN PREGNANCY (Date of issue: January 2019 , Version: 3 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Baclofen is a gamma-aminobutyric acid (GABA) agonist licensed for oral (...) or intrathecal administration to alleviate spasticity of voluntary muscle in patients with multiple sclerosis, spinal cord lesions, cerebral palsy, cerebrovascular accidents, traumatic head injury and meningitis. Data on the use of baclofen in human pregnancy are derived from one small cohort study (presented in abstract only), case reports and two small case series (one presented only in abstract), and as such, are too limited to accurately assess risks to the infant or pregnancy. An increased risk

2014 UK Teratology Information Service

14. Baclofen for alcohol withdrawal. (PubMed)

Baclofen for alcohol withdrawal. The treatment baclofen can rapidly reduce symptoms of severe alcohol withdrawal syndrome (AWS) in alcoholic patients, with a significant reduction in the cost. Baclofen is easy to manage, and rare euphoria, craving and other pleasant effects are reported by patients treated with baclofen.To assess the efficacy and safety of baclofen for patients with AWS.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (October (...) randomized controlled clinical trials (RCTs) evaluating baclofen versus placebo or any other treatment for patients with AWS. Uncontrolled, non-randomized or quasi-randomized trials were excluded. Both parallel group and cross-over design were included.Two review authors independently assessed references retrieved for possible inclusion. All disagreements were resolved by an independent party. Study authors were contacted for additional information. Adverse effects information was collected from

2013 Cochrane

15. Baclofen for alcohol withdrawal. (PubMed)

Baclofen for alcohol withdrawal. The treatment of baclofen can rapidly reduce symptoms of severe alcohol withdrawal syndrome (AWS) in alcoholic patients, with a significant reduction in the cost. Baclofen is easily manageable, what's more, no patient treated with baclofen reported euphoria or other pleasant effects caused by the drug and no subject reported any degree of craving for the drug.To assess the efficacy and safety of baclofen for patients with alcohol withdrawal syndrome.We searched (...) . All searches included non-English language literature.All randomised controlled clinical trials (RCTs) evaluating baclofen versus placebo or any other treatment for patients with AWS. Uncontrolled, non-randomised or quasi-randomised trials were excluded. Both parallel group and cross-over design were included.Two reviewers independently assessed references retrieved for possible inclusion. All disagreements were resolved by an independent party. Study authors were contacted for additional

2011 Cochrane

16. The Efficacy of Baclofen in Reducing Alcohol Consumption and Decreasing Alcohol Craving in Alcohol Dependent Adults

The Efficacy of Baclofen in Reducing Alcohol Consumption and Decreasing Alcohol Craving in Alcohol Dependent Adults "The Efficacy of Baclofen in Reducing Alcohol Consumption and Decreasin" by Kelsey Bock < > > > > > Title Author Date of Graduation 8-14-2010 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Annjanette Sommers MS, PA-C Second Advisor Rob Rosenow PharmD, OD Rights . Abstract Background: Many people suffer from alcoholism which (...) can be a debilitating disease. With only three medications on the market to treat alcoholism, research to find new pharmaceuticals is important. The recent publication of a book promoting baclofen, a GABA agonist normally used to treat spasticity, as a treatment for alcoholism, has brought public attention to the topic. For potential patients who have read the book and clinicians who treat alcoholism, this systematic review examines claims that baclofen decreases alcohol cravings and has

2010 Pacific University EBM Capstone Project

17. Gablofen (baclofen) Injection

Gablofen (baclofen) Injection Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Gablofen (baclofen) Injection Company: CNS Therapeutics, Inc. Application No.: 022462 Approval Date: 11/19/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: March 7

2010 FDA - Drug Approval Package

18. Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy? (PubMed)

Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy? Reflux inhibitors, like the gamma-aminobutyric acid type B (GABA(B)) receptor agonist, baclofen, block transient lower esophageal sphincter relaxations (TLESRs) and are proposed as an add-on therapy in patients with proton pump inhibitor (PPI)-resistant gastroesophageal reflux. However, as other mechanisms of reflux become more important in the presence of a hiatal hernia (HH (...) ), the efficacy of reflux inhibitors to reduce acid and non-acid exposure may be hampered. Therefore, we compared the effect of baclofen in patients with no HH (-HH) and those with a large HH during PPI treatment.A total of 27 gastroesophageal reflux disease (GERD) patients on PPI were included; 16 had -HH and 11 had a large (> or =3 cm) HH (+HH). During PPI treatment, the effect of baclofen (3 x 20 mg) on acid and non-acid reflux was evaluated in a randomized, double-blind, placebo-controlled cross-over

2009 EvidenceUpdates

19. Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity

Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity Bensmail D, Ward AB, Wissel J, Motta F, Saltuari L, Lissens J, Cros S, Beresniak A Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of intrathecal baclofen as a first treatment in the medical management of spasticity, in France. The authors concluded that initial baclofen could be cost-effective compared with usual care. The cost and effectiveness

2009 NHS Economic Evaluation Database.

20. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. (PubMed)

Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Intervention to achieve alcohol abstinence represents the most effective treatment for alcohol-dependent patients with liver cirrhosis; however, anticraving drugs might worsen liver disease. We aimed to investigate the effectiveness and safety of baclofen in achieving and maintaining alcohol abstinence in patients with liver (...) cirrhosis.Between October, 2003, and November, 2006, 148 alcohol-dependent patients with liver cirrhosis were referred to the Institute of Internal Medicine, Rome, Italy. 84 were randomly allocated either oral baclofen or placebo for 12 weeks. Primary outcome was proportion of patients achieving and maintaining alcohol abstinence. Measures of this outcome were total alcohol abstinence and cumulative abstinence duration, which were assessed at outpatient visits. Relapse was defined as alcohol intake of more than

2007 Lancet